Evidence map›Paper›PMID 35057635›Full record

ArticleHuman gene therapy2022

Hongjie Wang, Chang Li, Adebimpe O Obadan, Hannah Frizzell, Tien-Ying Hsiang, Sucheol Gil, Audrey Germond, Connie Fountain, Audrey Baldessari, Steve Roffler and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Molecular therapy. Advances · 2026
    Article
  2. Article
  3. Article
  4. Auto-expansion ofMolecular therapy. Methods & clinical development · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Hongjie WangDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.
Chang LiDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.
Adebimpe O ObadanDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Hannah FrizzellDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Tien-Ying HsiangDepartment of Immunology, University of Washington, Seattle, Washington, USA.
Sucheol GilDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.
Audrey GermondWashington National Primate Research Center, Seattle, Washington, USA.
Connie FountainWashington National Primate Research Center, Seattle, Washington, USA.
Audrey BaldessariWashington National Primate Research Center, Seattle, Washington, USA.
Steve RofflerInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Hans-Peter KiemStem and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0001-5949-4947
Deborah H FullerDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
André LieberDivision of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-6742-6266
University of Washington · USUniversity of Washington Medical Center · USFred Hutch Cancer Center · USInstitute of Biomedical Sciences, Academia Sinica · TW

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Ras-MAPK Regulation of Lymphatic Vessel Valve DevelopmentR01HL120888 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHILIP D KING · 2015 to 2026
$4.6M
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell DiseaseR01HL130040 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2016 to 2024
$4.3M
Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapyR01HL141781 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2018 to 2021
$2.3M
NHLBI NIH HHS R01 HL120888NHLBI NIH HHS R01 HL130040NHLBI NIH HHS R01 HL141781NIH HHS P51 OD010425
6 · The paper itself

Abstract

While SARS-CoV2 vaccines have shown an unprecedented success, the ongoing emergence of new variants and necessity to adjust vaccines justify the development of alternative prophylaxis and therapy approaches. Hematopoietic stem cell (HSC) gene therapy using a secreted CoV2 decoy receptor protein (sACE2-Ig) would involve a one-time intervention resulting in long-term protection against airway infection, viremia, and extrapulmonary symptoms. We recently developed a technically simple and portable

Indexed as

COVID-19RNA, ViralAnimalsCytokinesGenetic TherapyHematopoietic Stem CellsMacaca mulattaMiceMice, TransgenicSARS-CoV-2ViremiaCytokinesRNA, Viraldecoy receptorerythroid cellsin vivo HSC gene therapySARS-CoV2

Identifiers

PMID35057635
PMCPMC9063208
OpenAlexW4205701090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.